NCT03020199 - Study of the Efficacy of Early Intervention With Secukinumab 300 mg s.c. Compared to Narrow-band UVB in Patients With New-onset Moderate to Severe Plaque Psoriasis | Biotech Hunter

Enrollment

196

Participants

Timeline

Start Date

March 27, 2017

Primary Completion Date

November 30, 2021

Study Completion Date

June 16, 2023

Conditions

Plaque Psoriasis

Interventions

BIOLOGICAL

Secukinumab

Secukinumab (AIN457) 300 mg was administered in an open-label fashion according to label as 2 s.c. injections of secukinumab 150 mg (1-mL liquid formulation in a pre-filled syringe). Each 300-mg dose was provided as 2 pre-filled syringes of 150-mg secukinumab in a single box. Each syringe was labeled as AIN457 150 mg/1 mL.

RADIATION

nb-UVB

Narrow-band UVB applied in 1 or 2 cycles, each comprising a period of 12 weeks with 2 to 3 treatment sessions per week totaling 24 to 36 sessions per cycle. The application was performed according to the investigational site's protocol, taking into account the patient's skin type. A maximum dose of 3 J/cm2 on the body and 1 J/cm2 on the face was recommended

Trial Locations (44)

1181

Novartis Investigative Site, Ciudad Autonoma de Bs As

1407

Novartis Investigative Site, Sofia

1431

Novartis Investigative Site, Sofia

1632

Novartis Investigative Site, Sofia

4002

Novartis Investigative Site, Plovdiv

4400

Novartis Investigative Site, Nyíregyháza

5000

Novartis Investigative Site, Szolnok

5800

Novartis Investigative Site, Pleven

8200

Novartis Investigative Site, Aarhus N

10138

Novartis Investigative Site, Tallinn

10789

Novartis Investigative Site, Berlin

13353

Novartis Investigative Site, Berlin

13419

Novartis Investigative Site, Tallinn

28006

Novartis Investigative Site, Madrid

28031

Novartis Investigative Site, Madrid

28041

Novartis Investigative Site, Madrid

28922

Novartis Investigative Site, Alcorcón

33100

Novartis Investigative Site, Tampere

35010

Novartis Investigative Site, Las Palmas de Gran Canaria

46014

Novartis Investigative Site, Valencia

50406

Novartis Investigative Site, Tartu

60590

Novartis Investigative Site, Frankfurt

91054

Novartis Investigative Site, Erlangen

C1425DKG

Novartis Investigative Site, Buenos Aires

P3C 1X8

Novartis Investigative Site, Greater Sudbury

L3P 1X2

Novartis Investigative Site, Markham

FIN-20100

Novartis Investigative Site, Turku

15-879

Novartis Investigative Site, Bialystok

85-094

Novartis Investigative Site, Bydgoszcz

80-803

Novartis Investigative Site, Gdansk

31-070

Novartis Investigative Site, Krakow

90-436

Novartis Investigative Site, Lodz

90-647

Novartis Investigative Site, Lodz

08916

Novartis Investigative Site, Badalona

08003

Novartis Investigative Site, Barcelona

08036

Novartis Investigative Site, Barcelona

03010

Novartis Investigative Site, Alicante

413 46

Novartis Investigative Site, Gothenburg

214 28

Novartis Investigative Site, Malmo

CH-1011

Novartis Investigative Site, Lausanne

BD5 0NA

Novartis Investigative Site, Bradford

LS7 4SA

Novartis Investigative Site, Leeds

SE1 9RT

Novartis Investigative Site, London

M6 8HD

Novartis Investigative Site, Salford